Diaceutics PLC
LSE:DXRX

Watchlist Manager
Diaceutics PLC Logo
Diaceutics PLC
LSE:DXRX
Watchlist
Price: 117.5 GBX Market Closed
Market Cap: 99.2m GBX
Have any thoughts about
Diaceutics PLC?
Write Note

Intrinsic Value

The intrinsic value of one DXRX stock under the Base Case scenario is 155.79 GBX. Compared to the current market price of 117.5 GBX, Diaceutics PLC is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DXRX Intrinsic Value
155.79 GBX
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Diaceutics PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DXRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DXRX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Diaceutics PLC

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Diaceutics PLC

Provide an overview of the primary business activities
of Diaceutics PLC.

What unique competitive advantages
does Diaceutics PLC hold over its rivals?

What risks and challenges
does Diaceutics PLC face in the near future?

Summarize the latest earnings call
of Diaceutics PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Diaceutics PLC.

Provide P/S
for Diaceutics PLC.

Provide P/E
for Diaceutics PLC.

Provide P/OCF
for Diaceutics PLC.

Provide P/FCFE
for Diaceutics PLC.

Provide P/B
for Diaceutics PLC.

Provide EV/S
for Diaceutics PLC.

Provide EV/GP
for Diaceutics PLC.

Provide EV/EBITDA
for Diaceutics PLC.

Provide EV/EBIT
for Diaceutics PLC.

Provide EV/OCF
for Diaceutics PLC.

Provide EV/FCFF
for Diaceutics PLC.

Provide EV/IC
for Diaceutics PLC.

Show me price targets
for Diaceutics PLC made by professional analysts.

What are the Revenue projections
for Diaceutics PLC?

How accurate were the past Revenue estimates
for Diaceutics PLC?

What are the Net Income projections
for Diaceutics PLC?

How accurate were the past Net Income estimates
for Diaceutics PLC?

What are the EPS projections
for Diaceutics PLC?

How accurate were the past EPS estimates
for Diaceutics PLC?

What are the EBIT projections
for Diaceutics PLC?

How accurate were the past EBIT estimates
for Diaceutics PLC?

Compare the revenue forecasts
for Diaceutics PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Diaceutics PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Diaceutics PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Diaceutics PLC compared to its peers.

Compare the P/E ratios
of Diaceutics PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Diaceutics PLC with its peers.

Analyze the financial leverage
of Diaceutics PLC compared to its main competitors.

Show all profitability ratios
for Diaceutics PLC.

Provide ROE
for Diaceutics PLC.

Provide ROA
for Diaceutics PLC.

Provide ROIC
for Diaceutics PLC.

Provide ROCE
for Diaceutics PLC.

Provide Gross Margin
for Diaceutics PLC.

Provide Operating Margin
for Diaceutics PLC.

Provide Net Margin
for Diaceutics PLC.

Provide FCF Margin
for Diaceutics PLC.

Show all solvency ratios
for Diaceutics PLC.

Provide D/E Ratio
for Diaceutics PLC.

Provide D/A Ratio
for Diaceutics PLC.

Provide Interest Coverage Ratio
for Diaceutics PLC.

Provide Altman Z-Score Ratio
for Diaceutics PLC.

Provide Quick Ratio
for Diaceutics PLC.

Provide Current Ratio
for Diaceutics PLC.

Provide Cash Ratio
for Diaceutics PLC.

What is the historical Revenue growth
over the last 5 years for Diaceutics PLC?

What is the historical Net Income growth
over the last 5 years for Diaceutics PLC?

What is the current Free Cash Flow
of Diaceutics PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Diaceutics PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Diaceutics PLC

Current Assets 27.2m
Cash & Short-Term Investments 16.7m
Receivables 9.7m
Other Current Assets 796k
Non-Current Assets 18.2m
PP&E 1.8m
Intangibles 14.5m
Other Non-Current Assets 1.9m
Current Liabilities 5.6m
Accounts Payable 610k
Accrued Liabilities 3.7m
Other Current Liabilities 1.3m
Non-Current Liabilities 1.1m
Long-Term Debt 984k
Other Non-Current Liabilities 89k
Efficiency

Earnings Waterfall
Diaceutics PLC

Revenue
26.1m GBP
Cost of Revenue
-4.4m GBP
Gross Profit
21.7m GBP
Operating Expenses
-26.2m GBP
Operating Income
-4.4m GBP
Other Expenses
1.6m GBP
Net Income
-2.8m GBP

Free Cash Flow Analysis
Diaceutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Diaceutics reported strong top-line growth with a revenue increase of 24%, reaching GBP 12.3 million for H1 2024. The company continues to shift towards subscription-based revenue, achieving a record order book of GBP 27.9 million, with 93% of subscriptions renewed. The EBITDA loss widened to GBP 1.3 million due to ongoing investments, but profitability and cash flow generation are anticipated by 2025. The company maintains a strong balance sheet with GBP 16.7 million in cash and no debt. Over 250,000 patients were identified through their Signal platform, expecting to impact over 500,000 lives by year-end.

What is Earnings Call?
Fundamental Scores

DXRX Profitability Score
Profitability Due Diligence

Diaceutics PLC's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Positive 1-Year Revenue Growth
39/100
Profitability
Score

Diaceutics PLC's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

DXRX Solvency Score
Solvency Due Diligence

Diaceutics PLC's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Diaceutics PLC's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DXRX Price Targets Summary
Diaceutics PLC

Wall Street analysts forecast DXRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DXRX is 178.91 GBX with a low forecast of 161.6 GBX and a high forecast of 210 GBX.

Lowest
Price Target
161.6 GBX
38% Upside
Average
Price Target
178.91 GBX
52% Upside
Highest
Price Target
210 GBX
79% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DXRX?

Click here to dive deeper.

Dividends

Diaceutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for DXRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Diaceutics PLC Logo
Diaceutics PLC

Country

United Kingdom

Industry

Life Sciences Tools & Services

Market Cap

99.5m GBP

Dividend Yield

0%

Description

Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, laboratory tech support and others. The firm has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.

Contact

NORTHERN IRELAND
Belfast
Titanic Suites Enterprise House, 55-59 Adelaide Street
www.diaceutics.com

IPO

2019-03-21

Employees

120

Officers

Founder & Executive Chairman
Mr. Peter Keeling
CEO & Director
Mr. Ryan Keeling
CFO & Director
Mr. Nicholas Stewart Roberts
Vice President of Scientific & Medical Services
Ken Ruppel
General Counsel
Ms. Gillian Shaw
Vice President of Marketing
Amie McNiece
Show More
Interim VP of Sales
Marianna Sciortino
Chief People Officer
Ms. Sandra Blake
Chief Data Officer? & Executive Director
Mr. Jordan Russell Clark
Chief Precision Medicine Officer
Ms. Susanne Munksted
Show Less

See Also

Discover More
What is the Intrinsic Value of one DXRX stock?

The intrinsic value of one DXRX stock under the Base Case scenario is 155.79 GBX.

Is DXRX stock undervalued or overvalued?

Compared to the current market price of 117.5 GBX, Diaceutics PLC is Undervalued by 25%.

Back to Top